Dengue Blocked, Viral Load Dropped, Hope Unlocked--High-Dose Mosnodenvir Delivers 💊🚀🛡️

Thrilled to see a major step forward in dengue prevention! 🦟💊 A new NEJM study reports that daily mosnodenvir, a first-in-class antiviral targeting the NS3–NS4B interaction, significantly reduced DENV-3 viral load and prevented infection in a controlled human challenge model. 📉🧬 It's early, but the results offer real hope for a long-awaited oral dengue prophylaxis—with encouraging safety, strong PK, and dose-dependent efficacy. 🚀🌍 Exciting moment for global infectious-disease innovation and antiviral development. 🙌✨